Profile data is unavailable for this security.
About the company
Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.
- Revenue in AUD (TTM)1.39m
- Net income in AUD-3.54m
- Incorporated2006
- Employees15.00
- LocationPatrys LtdLevel 4, 96-100 Albert RoadSOUTH MELBOURNE 3205AustraliaAUS
- Phone+61 39670-3273
- Fax+61 39670-3247
- Websitehttps://patrys.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
Hexima Ltd | 61.67k | -933.87k | 2.84m | -- | -- | 0.1406 | -- | 46.05 | -0.0559 | -0.0559 | 0.0037 | 0.121 | 0.0236 | -- | 0.1523 | -- | -35.74 | -74.86 | -38.89 | -189.88 | -- | -- | -1,514.30 | -274.35 | -- | -- | 0.00 | -- | -95.85 | -55.24 | 51.33 | -- | -- | -- |
Vectus Biosystems Ltd | 76.86k | -2.34m | 4.26m | -- | -- | 2.86 | -- | 55.38 | -0.044 | -0.044 | 0.0014 | 0.0279 | 0.0231 | -- | 0.0638 | -- | -70.26 | -84.62 | -88.42 | -227.56 | -- | -- | -3,042.06 | -12,407.49 | 3.45 | -389.35 | 0.00 | -- | 38.46 | 222.59 | 32.07 | -- | -- | -- |
Cambium Bio Ltd | 128.99k | -2.26m | 4.65m | -- | -- | 1.68 | -- | 36.07 | -0.4599 | -0.4599 | 0.0173 | 0.2327 | 0.0318 | -- | 1.00 | -- | -55.60 | -30.97 | -144.62 | -99.20 | 62.39 | -- | -1,748.79 | -74.07 | -- | -149.70 | 0.1443 | -- | -- | -- | -33.72 | -- | -- | -- |
Neuroscientific Biopharmaceuticals Ltd | 2.39m | 324.21k | 5.21m | -- | 15.86 | 0.973 | 12.53 | 2.18 | 0.0023 | 0.0023 | 0.0165 | 0.037 | 0.4458 | -- | 48.82 | -- | 6.04 | -46.72 | 6.46 | -51.16 | -- | -- | 13.56 | -199.33 | -- | 33.42 | 0.00 | -- | -52.76 | 82.13 | 130.34 | -- | -37.50 | -- |
Invex Therapeutics Ltd | 1.70m | -1.64m | 6.24m | -- | -- | 1.10 | -- | 3.66 | -0.0218 | -0.0218 | 0.0227 | 0.0757 | 0.1178 | -- | 7.95 | -- | -11.35 | -15.73 | -12.20 | -16.55 | -- | -- | -96.35 | -535.37 | -- | -- | 0.00 | -- | 35.66 | 566.05 | 78.81 | -- | -- | -- |
Avecho Biotechnology Ltd | 339.30k | -3.48m | 6.34m | 29.00 | -- | 1.50 | -- | 18.68 | -0.0012 | -0.0012 | 0.0001 | 0.0013 | 0.0693 | 4.26 | 0.7043 | -- | -71.20 | -47.08 | -105.46 | -55.25 | -45.60 | 78.67 | -1,026.91 | -156.43 | 3.48 | -- | 0.0316 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
Holista Colltech Limited | 5.46m | -4.64m | 6.41m | 3.00 | -- | -- | -- | 1.17 | -0.0166 | -0.0166 | 0.0196 | -0.0094 | 1.48 | 3.54 | 5.39 | -- | -125.43 | -42.59 | -1,528.79 | -63.58 | 51.69 | 56.37 | -85.04 | -39.27 | 0.2094 | -282.55 | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
Patrys Ltd | 1.39m | -3.54m | 7.20m | 15.00 | -- | 2.07 | -- | 5.17 | -0.0017 | -0.0017 | 0.0007 | 0.0017 | 0.2386 | -- | 0.6665 | -- | -60.57 | -52.81 | -68.65 | -56.79 | -- | -- | -253.86 | -249.64 | -- | -- | 0.00 | -- | -51.11 | 10.55 | 49.88 | -- | -4.41 | -- |
Zelira Therapeutics Ltd | 1.02m | -36.57m | 8.34m | 8.00 | -- | -- | -- | 8.14 | -3.22 | -3.22 | 0.0902 | -0.3979 | 0.0524 | 0.0609 | 5.06 | -- | -188.05 | -46.98 | -246.20 | -50.16 | 91.73 | -- | -3,587.90 | -1,063.82 | 0.424 | -6.78 | 3.35 | -- | -82.72 | -35.59 | -556.18 | -- | -- | -- |
Algorae Pharmaceuticals Ltd | 125.20k | -2.10m | 10.12m | -- | -- | 3.36 | -- | 80.87 | -0.0013 | -0.0013 | 0.00008 | 0.0018 | 0.0338 | -- | 1.81 | -- | -56.60 | -47.73 | -61.85 | -54.26 | -- | -- | -1,673.77 | -865.45 | -- | -115.69 | 0.00 | -- | 197.95 | -30.46 | 0.5741 | -- | -- | -- |
Adalta Ltd | 1.78m | -5.38m | 10.91m | -- | -- | 5.28 | -- | 6.11 | -0.0111 | -0.0111 | 0.0036 | 0.0034 | 0.2682 | -- | 0.7681 | -- | -80.88 | -66.85 | -203.94 | -114.23 | -- | -- | -301.55 | -175.59 | -- | -51.02 | 0.5712 | -- | -49.47 | -13.04 | -10.93 | -- | -18.22 | -- |
Chimeric Therapeutics Ltd | 0.00 | -12.53m | 12.67m | -- | -- | 4.97 | -- | -- | -0.0136 | -0.0136 | 0.00 | 0.0028 | 0.00 | -- | -- | -- | -66.56 | -- | -194.88 | -- | -- | -- | -- | -- | -- | -58.48 | 0.5228 | -- | -- | -- | 50.86 | -- | -- | -- |